Observed Effectiveness of Palivizumab for 29-36-Week Gestation Infants
Respiratory syncytial virus (RSV) is a common reason for hospitalization of infants. In clinical trials, palivizumab reduced RSV hospitalization rates for premature infants. The 2014 American Academy of Pediatrics clinical practice guideline advised against use of palivizumab for otherwise healthy i...
Gespeichert in:
| Veröffentlicht in: | Pediatrics (Evanston) 2016-08, Vol.138 (2), p.1 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 2 |
| container_start_page | 1 |
| container_title | Pediatrics (Evanston) |
| container_volume | 138 |
| creator | Farber, Harold J Buckwold, Frederick J Lachman, Barry Simpson, J Scott Buck, Ernest Arun, Matha Valadez, Adolfo M Ruiz, Teresa Alonzo, Joy Henry, Andrea Cos-Okpalla, Nneka Nguyen, Kelsey Brendel, William Small, James Glomb, William Brendle |
| description | Respiratory syncytial virus (RSV) is a common reason for hospitalization of infants. In clinical trials, palivizumab reduced RSV hospitalization rates for premature infants. The 2014 American Academy of Pediatrics clinical practice guideline advised against use of palivizumab for otherwise healthy infants ≥29 weeks' gestation. The aim of this study was to determine the effect of palivizumab administration on hospitalization rates for RSV and bronchiolitis without RSV diagnosis among infants 29 to 36 weeks' gestation who do not have chronic illness.
Claims data were extracted from databases of 9 Texas Medicaid managed care programs. Eligible infants were 29 to 36 weeks' gestation, without claims suggesting chronic illness, and who were born between April 1 and December 31 of 2012, 2013, and 2014.
A total of 2031 eligible infants of 29 to 32 weeks' gestation and 12 066 infants of 33 to 36 weeks' gestation were identified; 41.5% of the infants 29 to 32 weeks' gestation and 3.7% of the infants 33 to 36 weeks' gestation had paid claims for dispensing of ≥1 palivizumab doses. Among the infants of 29 to 32 weeks' gestation, palivizumab dispensing was associated with reduced RSV hospitalization rates (3.1% vs 5.0%, P = .04) but increased hospitalizations for bronchiolitis without RSV diagnosis (3.3% vs 1.9%, P = .05). There were no significant differences by palivizumab administration status for the infants of 33 to 36 weeks' gestation.
Among infants 29 to 32 weeks' gestation without chronic illness, palivizumab use was associated with reduced RSV hospitalizations but increased hospitalizations for bronchiolitis without RSV diagnosis. |
| doi_str_mv | 10.1542/peds.2016-0627 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_1808606606</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A561095303</galeid><sourcerecordid>A561095303</sourcerecordid><originalsourceid>FETCH-LOGICAL-c401t-8c464d49613204747fc95560a27d15d4af13ee77b0ebcc92276a7136b2833fd03</originalsourceid><addsrcrecordid>eNpdkU1r3DAQQEVoyW6TXHMshl5y0Wb0bR-XJUkDgc2hIUchy6PgxGttLXtp--sjs2kPhQFd3ojHPEIuGayYkvx6j01acWCagubmhCwZVCWV3KhPZAkgGJUAakG-pPQKAFIZfkoW3EjBSwVLcrutEw4HbIqbENCP7QF7TKmIoXh0XXto_0w7VxchDgWvqND0GfGtuMM0urGNfXHfB9eP6Zx8Dq5LePHxnpGn25sfm-_0YXt3v1k_UC-BjbT0UstGVpoJDtJIE3yllAbHTcNUI11gAtGYGrD2vuLcaGeY0DUvhQgNiDNydfx3P8SfU7awuzZ57DrXY5ySZSWUGnSejH77D32N09Bnu0wxXgEzSmWKHqkX16Ftex_7EX-NPnYdvqDN8putXSudz6oEiMyvjrwfYkoDBrsf2p0bflsGdi5i5yJ2LmLnInnh64fGVO-w-Yf_TSDeATdhgwM</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1812901755</pqid></control><display><type>article</type><title>Observed Effectiveness of Palivizumab for 29-36-Week Gestation Infants</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Farber, Harold J ; Buckwold, Frederick J ; Lachman, Barry ; Simpson, J Scott ; Buck, Ernest ; Arun, Matha ; Valadez, Adolfo M ; Ruiz, Teresa ; Alonzo, Joy ; Henry, Andrea ; Cos-Okpalla, Nneka ; Nguyen, Kelsey ; Brendel, William ; Small, James ; Glomb, William Brendle</creator><creatorcontrib>Farber, Harold J ; Buckwold, Frederick J ; Lachman, Barry ; Simpson, J Scott ; Buck, Ernest ; Arun, Matha ; Valadez, Adolfo M ; Ruiz, Teresa ; Alonzo, Joy ; Henry, Andrea ; Cos-Okpalla, Nneka ; Nguyen, Kelsey ; Brendel, William ; Small, James ; Glomb, William Brendle</creatorcontrib><description>Respiratory syncytial virus (RSV) is a common reason for hospitalization of infants. In clinical trials, palivizumab reduced RSV hospitalization rates for premature infants. The 2014 American Academy of Pediatrics clinical practice guideline advised against use of palivizumab for otherwise healthy infants ≥29 weeks' gestation. The aim of this study was to determine the effect of palivizumab administration on hospitalization rates for RSV and bronchiolitis without RSV diagnosis among infants 29 to 36 weeks' gestation who do not have chronic illness.
Claims data were extracted from databases of 9 Texas Medicaid managed care programs. Eligible infants were 29 to 36 weeks' gestation, without claims suggesting chronic illness, and who were born between April 1 and December 31 of 2012, 2013, and 2014.
A total of 2031 eligible infants of 29 to 32 weeks' gestation and 12 066 infants of 33 to 36 weeks' gestation were identified; 41.5% of the infants 29 to 32 weeks' gestation and 3.7% of the infants 33 to 36 weeks' gestation had paid claims for dispensing of ≥1 palivizumab doses. Among the infants of 29 to 32 weeks' gestation, palivizumab dispensing was associated with reduced RSV hospitalization rates (3.1% vs 5.0%, P = .04) but increased hospitalizations for bronchiolitis without RSV diagnosis (3.3% vs 1.9%, P = .05). There were no significant differences by palivizumab administration status for the infants of 33 to 36 weeks' gestation.
Among infants 29 to 32 weeks' gestation without chronic illness, palivizumab use was associated with reduced RSV hospitalizations but increased hospitalizations for bronchiolitis without RSV diagnosis.</description><identifier>ISSN: 0031-4005</identifier><identifier>EISSN: 1098-4275</identifier><identifier>DOI: 10.1542/peds.2016-0627</identifier><identifier>PMID: 27432850</identifier><identifier>CODEN: PEDIAU</identifier><language>eng</language><publisher>United States: American Academy of Pediatrics</publisher><subject>Analysis ; Antiviral Agents - therapeutic use ; Babies ; Bronchiolitis ; Bronchiolitis - drug therapy ; Chronic illnesses ; Dosage and administration ; Drug therapy ; Gestational Age ; Health aspects ; Hospitalization ; Humans ; Infant ; Infants ; Medicaid ; Palivizumab ; Palivizumab - therapeutic use ; Pediatric research ; Pediatrics ; Practice guidelines (Medicine) ; Pregnancy ; Respiratory syncytial virus ; Respiratory Syncytial Virus Infections - drug therapy ; Treatment Outcome</subject><ispartof>Pediatrics (Evanston), 2016-08, Vol.138 (2), p.1</ispartof><rights>Copyright © 2016 by the American Academy of Pediatrics.</rights><rights>Copyright American Academy of Pediatrics Aug 2016</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c401t-8c464d49613204747fc95560a27d15d4af13ee77b0ebcc92276a7136b2833fd03</citedby><cites>FETCH-LOGICAL-c401t-8c464d49613204747fc95560a27d15d4af13ee77b0ebcc92276a7136b2833fd03</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27432850$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Farber, Harold J</creatorcontrib><creatorcontrib>Buckwold, Frederick J</creatorcontrib><creatorcontrib>Lachman, Barry</creatorcontrib><creatorcontrib>Simpson, J Scott</creatorcontrib><creatorcontrib>Buck, Ernest</creatorcontrib><creatorcontrib>Arun, Matha</creatorcontrib><creatorcontrib>Valadez, Adolfo M</creatorcontrib><creatorcontrib>Ruiz, Teresa</creatorcontrib><creatorcontrib>Alonzo, Joy</creatorcontrib><creatorcontrib>Henry, Andrea</creatorcontrib><creatorcontrib>Cos-Okpalla, Nneka</creatorcontrib><creatorcontrib>Nguyen, Kelsey</creatorcontrib><creatorcontrib>Brendel, William</creatorcontrib><creatorcontrib>Small, James</creatorcontrib><creatorcontrib>Glomb, William Brendle</creatorcontrib><title>Observed Effectiveness of Palivizumab for 29-36-Week Gestation Infants</title><title>Pediatrics (Evanston)</title><addtitle>Pediatrics</addtitle><description>Respiratory syncytial virus (RSV) is a common reason for hospitalization of infants. In clinical trials, palivizumab reduced RSV hospitalization rates for premature infants. The 2014 American Academy of Pediatrics clinical practice guideline advised against use of palivizumab for otherwise healthy infants ≥29 weeks' gestation. The aim of this study was to determine the effect of palivizumab administration on hospitalization rates for RSV and bronchiolitis without RSV diagnosis among infants 29 to 36 weeks' gestation who do not have chronic illness.
Claims data were extracted from databases of 9 Texas Medicaid managed care programs. Eligible infants were 29 to 36 weeks' gestation, without claims suggesting chronic illness, and who were born between April 1 and December 31 of 2012, 2013, and 2014.
A total of 2031 eligible infants of 29 to 32 weeks' gestation and 12 066 infants of 33 to 36 weeks' gestation were identified; 41.5% of the infants 29 to 32 weeks' gestation and 3.7% of the infants 33 to 36 weeks' gestation had paid claims for dispensing of ≥1 palivizumab doses. Among the infants of 29 to 32 weeks' gestation, palivizumab dispensing was associated with reduced RSV hospitalization rates (3.1% vs 5.0%, P = .04) but increased hospitalizations for bronchiolitis without RSV diagnosis (3.3% vs 1.9%, P = .05). There were no significant differences by palivizumab administration status for the infants of 33 to 36 weeks' gestation.
Among infants 29 to 32 weeks' gestation without chronic illness, palivizumab use was associated with reduced RSV hospitalizations but increased hospitalizations for bronchiolitis without RSV diagnosis.</description><subject>Analysis</subject><subject>Antiviral Agents - therapeutic use</subject><subject>Babies</subject><subject>Bronchiolitis</subject><subject>Bronchiolitis - drug therapy</subject><subject>Chronic illnesses</subject><subject>Dosage and administration</subject><subject>Drug therapy</subject><subject>Gestational Age</subject><subject>Health aspects</subject><subject>Hospitalization</subject><subject>Humans</subject><subject>Infant</subject><subject>Infants</subject><subject>Medicaid</subject><subject>Palivizumab</subject><subject>Palivizumab - therapeutic use</subject><subject>Pediatric research</subject><subject>Pediatrics</subject><subject>Practice guidelines (Medicine)</subject><subject>Pregnancy</subject><subject>Respiratory syncytial virus</subject><subject>Respiratory Syncytial Virus Infections - drug therapy</subject><subject>Treatment Outcome</subject><issn>0031-4005</issn><issn>1098-4275</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpdkU1r3DAQQEVoyW6TXHMshl5y0Wb0bR-XJUkDgc2hIUchy6PgxGttLXtp--sjs2kPhQFd3ojHPEIuGayYkvx6j01acWCagubmhCwZVCWV3KhPZAkgGJUAakG-pPQKAFIZfkoW3EjBSwVLcrutEw4HbIqbENCP7QF7TKmIoXh0XXto_0w7VxchDgWvqND0GfGtuMM0urGNfXHfB9eP6Zx8Dq5LePHxnpGn25sfm-_0YXt3v1k_UC-BjbT0UstGVpoJDtJIE3yllAbHTcNUI11gAtGYGrD2vuLcaGeY0DUvhQgNiDNydfx3P8SfU7awuzZ57DrXY5ySZSWUGnSejH77D32N09Bnu0wxXgEzSmWKHqkX16Ftex_7EX-NPnYdvqDN8putXSudz6oEiMyvjrwfYkoDBrsf2p0bflsGdi5i5yJ2LmLnInnh64fGVO-w-Yf_TSDeATdhgwM</recordid><startdate>201608</startdate><enddate>201608</enddate><creator>Farber, Harold J</creator><creator>Buckwold, Frederick J</creator><creator>Lachman, Barry</creator><creator>Simpson, J Scott</creator><creator>Buck, Ernest</creator><creator>Arun, Matha</creator><creator>Valadez, Adolfo M</creator><creator>Ruiz, Teresa</creator><creator>Alonzo, Joy</creator><creator>Henry, Andrea</creator><creator>Cos-Okpalla, Nneka</creator><creator>Nguyen, Kelsey</creator><creator>Brendel, William</creator><creator>Small, James</creator><creator>Glomb, William Brendle</creator><general>American Academy of Pediatrics</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TS</scope><scope>7U9</scope><scope>H94</scope><scope>K9.</scope><scope>M7N</scope><scope>NAPCQ</scope><scope>U9A</scope><scope>7X8</scope></search><sort><creationdate>201608</creationdate><title>Observed Effectiveness of Palivizumab for 29-36-Week Gestation Infants</title><author>Farber, Harold J ; Buckwold, Frederick J ; Lachman, Barry ; Simpson, J Scott ; Buck, Ernest ; Arun, Matha ; Valadez, Adolfo M ; Ruiz, Teresa ; Alonzo, Joy ; Henry, Andrea ; Cos-Okpalla, Nneka ; Nguyen, Kelsey ; Brendel, William ; Small, James ; Glomb, William Brendle</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c401t-8c464d49613204747fc95560a27d15d4af13ee77b0ebcc92276a7136b2833fd03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Analysis</topic><topic>Antiviral Agents - therapeutic use</topic><topic>Babies</topic><topic>Bronchiolitis</topic><topic>Bronchiolitis - drug therapy</topic><topic>Chronic illnesses</topic><topic>Dosage and administration</topic><topic>Drug therapy</topic><topic>Gestational Age</topic><topic>Health aspects</topic><topic>Hospitalization</topic><topic>Humans</topic><topic>Infant</topic><topic>Infants</topic><topic>Medicaid</topic><topic>Palivizumab</topic><topic>Palivizumab - therapeutic use</topic><topic>Pediatric research</topic><topic>Pediatrics</topic><topic>Practice guidelines (Medicine)</topic><topic>Pregnancy</topic><topic>Respiratory syncytial virus</topic><topic>Respiratory Syncytial Virus Infections - drug therapy</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Farber, Harold J</creatorcontrib><creatorcontrib>Buckwold, Frederick J</creatorcontrib><creatorcontrib>Lachman, Barry</creatorcontrib><creatorcontrib>Simpson, J Scott</creatorcontrib><creatorcontrib>Buck, Ernest</creatorcontrib><creatorcontrib>Arun, Matha</creatorcontrib><creatorcontrib>Valadez, Adolfo M</creatorcontrib><creatorcontrib>Ruiz, Teresa</creatorcontrib><creatorcontrib>Alonzo, Joy</creatorcontrib><creatorcontrib>Henry, Andrea</creatorcontrib><creatorcontrib>Cos-Okpalla, Nneka</creatorcontrib><creatorcontrib>Nguyen, Kelsey</creatorcontrib><creatorcontrib>Brendel, William</creatorcontrib><creatorcontrib>Small, James</creatorcontrib><creatorcontrib>Glomb, William Brendle</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Physical Education Index</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Nursing & Allied Health Premium</collection><collection>MEDLINE - Academic</collection><jtitle>Pediatrics (Evanston)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Farber, Harold J</au><au>Buckwold, Frederick J</au><au>Lachman, Barry</au><au>Simpson, J Scott</au><au>Buck, Ernest</au><au>Arun, Matha</au><au>Valadez, Adolfo M</au><au>Ruiz, Teresa</au><au>Alonzo, Joy</au><au>Henry, Andrea</au><au>Cos-Okpalla, Nneka</au><au>Nguyen, Kelsey</au><au>Brendel, William</au><au>Small, James</au><au>Glomb, William Brendle</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Observed Effectiveness of Palivizumab for 29-36-Week Gestation Infants</atitle><jtitle>Pediatrics (Evanston)</jtitle><addtitle>Pediatrics</addtitle><date>2016-08</date><risdate>2016</risdate><volume>138</volume><issue>2</issue><spage>1</spage><pages>1-</pages><issn>0031-4005</issn><eissn>1098-4275</eissn><coden>PEDIAU</coden><abstract>Respiratory syncytial virus (RSV) is a common reason for hospitalization of infants. In clinical trials, palivizumab reduced RSV hospitalization rates for premature infants. The 2014 American Academy of Pediatrics clinical practice guideline advised against use of palivizumab for otherwise healthy infants ≥29 weeks' gestation. The aim of this study was to determine the effect of palivizumab administration on hospitalization rates for RSV and bronchiolitis without RSV diagnosis among infants 29 to 36 weeks' gestation who do not have chronic illness.
Claims data were extracted from databases of 9 Texas Medicaid managed care programs. Eligible infants were 29 to 36 weeks' gestation, without claims suggesting chronic illness, and who were born between April 1 and December 31 of 2012, 2013, and 2014.
A total of 2031 eligible infants of 29 to 32 weeks' gestation and 12 066 infants of 33 to 36 weeks' gestation were identified; 41.5% of the infants 29 to 32 weeks' gestation and 3.7% of the infants 33 to 36 weeks' gestation had paid claims for dispensing of ≥1 palivizumab doses. Among the infants of 29 to 32 weeks' gestation, palivizumab dispensing was associated with reduced RSV hospitalization rates (3.1% vs 5.0%, P = .04) but increased hospitalizations for bronchiolitis without RSV diagnosis (3.3% vs 1.9%, P = .05). There were no significant differences by palivizumab administration status for the infants of 33 to 36 weeks' gestation.
Among infants 29 to 32 weeks' gestation without chronic illness, palivizumab use was associated with reduced RSV hospitalizations but increased hospitalizations for bronchiolitis without RSV diagnosis.</abstract><cop>United States</cop><pub>American Academy of Pediatrics</pub><pmid>27432850</pmid><doi>10.1542/peds.2016-0627</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0031-4005 |
| ispartof | Pediatrics (Evanston), 2016-08, Vol.138 (2), p.1 |
| issn | 0031-4005 1098-4275 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1808606606 |
| source | MEDLINE; EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
| subjects | Analysis Antiviral Agents - therapeutic use Babies Bronchiolitis Bronchiolitis - drug therapy Chronic illnesses Dosage and administration Drug therapy Gestational Age Health aspects Hospitalization Humans Infant Infants Medicaid Palivizumab Palivizumab - therapeutic use Pediatric research Pediatrics Practice guidelines (Medicine) Pregnancy Respiratory syncytial virus Respiratory Syncytial Virus Infections - drug therapy Treatment Outcome |
| title | Observed Effectiveness of Palivizumab for 29-36-Week Gestation Infants |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-14T09%3A15%3A01IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Observed%20Effectiveness%20of%20Palivizumab%20for%2029-36-Week%20Gestation%20Infants&rft.jtitle=Pediatrics%20(Evanston)&rft.au=Farber,%20Harold%20J&rft.date=2016-08&rft.volume=138&rft.issue=2&rft.spage=1&rft.pages=1-&rft.issn=0031-4005&rft.eissn=1098-4275&rft.coden=PEDIAU&rft_id=info:doi/10.1542/peds.2016-0627&rft_dat=%3Cgale_proqu%3EA561095303%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1812901755&rft_id=info:pmid/27432850&rft_galeid=A561095303&rfr_iscdi=true |